Created On: 2020-07-15
Record Count: 11
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 203461
Patent Application: 60/4S6,921; March 21, 2003 (TITLE: NASAL CALCITONIN FORMULATIONS CONTAINING CHLOROBUT ANOL)
Patent Rights means (i) the patents and patent applications listed; (ii) all continuation, divisional, continuation-in-part, continued prosecution, re-examination, reissue, utility model, petty, and other patent applications claiming subject matter therein or claiming priority from any of the foregoing and all patents that issue therefrom; (iii) all counterparts, substitutions, restorations, extensions (including, without limitation, patent term extensions), supplementary protection certificates, registrations, confirmations, validations and renewals of any of the foregoing; and (iv) all other U.S. patents, patent applications (provisional and non-provisional), utility models, invention certificates, and other grants for the protection of inventions or industrial designs, in each case that are Controlled by Licensor or its Affiliates now or in the future and that cover or are useful for the Product or the making (including development, testing, packaging, and Manufacturing), preparation, importation, use, or sale of the Product.
IPSCIO Record ID: 271451
The Parties also agree hereby on the financial compensation for the assignment by Assignor to Assignee and/or its Affiliates of any rights on and to Future Results including any rights as a co-inventor of patentable inventions to be covered by Future Patent Applications.
The provisions of this Agreement shall only apply to Results generated by Assignor during the period ending on the earlier of (i) the term of this Agreement and (ii) the Employment Period.
No. 1. The French patent application nÂ°FR1753775 filed on April, 28th 2017 and entitled â€œ20-Hydroecdysone extract of pharmaceutical grade, its use and its preparationâ€.
No. 2. The French patent application nÂ°FR1758071 filed on May, 31st 2017 and entitled â€œUse of 20-hydroxyecdysone and the derivatives thereof in the treatment of myopathiesâ€.
No. 3. The French patent application nÂ°FR1851778 filed on February, 28th 2018 and entitled â€œPhytoecdysones for their use in the prevention of the loss of muscular strength during an immobilisationâ€ .
No. 4. The French patent application nÂ°FR 1902726, entitled â€œPhytoecdysones and their derivatives for their use in the treatment of neuromuscular diseases â€œ.
No. 5. The French patent application nÂ°FR 1902727, entitled â€œPhytoecdysones and their derivatives for their use in the treatment of alterations of the respiratory functionâ€.
As well as any and all (I) provisional and non-provisional applications, foreign patent application, patent cooperation treaty (PCT) applications, substitutions, continuations, continuations-in-part, divisions and renewals of the above describe patent applications, (ii) all patents granted thereon, and (iii) all reissues, re-examinations and extensions or restorations, including supplementary protection certificates or the equivalent thereof, granted thereon and corresponding priority rights.
Existing Patents means the patent applications filed by Licensee before July 13, 2015 as well as any and all (I) provisional and non-provisional applications, foreign patent application, patent cooperation treaty (PCT) applications, substitutions, continuations, continuations-in-part, divisions and renewals of such patent applications, (ii) all patents granted thereon, and (iii) all reissues, re-examinations and extensions or restorations, including supplementary protection certificates or the equivalent thereof, granted thereon and corresponding priority rights.
Future Patent Application means (I) any patent or patent application based on Current Results for which Assignor is designated as an inventor or co-inventor and/or (ii) a patent application filed on the basis of Future Results and for which Licensor is designated as an inventor or co-inventor, as well as any and all (x) provisional and non-provisional applications, foreign patent application, patent cooperation treaty (PCT) applications, substitutions, continuations, continuations-in-part, divisions and renewals of such patent applications described in (I) and (ii), (y) all patents granted thereon, and (z) all reissues, re-examinations and extensions or restorations, including supplementary protection certificates or the equivalent thereof, granted thereon and corresponding priority rights.
The myopathies are neuromuscular disorders in which the primary symptom is muscle weakness due to dysfunction of muscle fiber.
IPSCIO Record ID: 282838
Licensor Patents means (a) those Patents set forth hereto (the Initial Licensor Patents); (b) any other Patents owned, licensed, or controlled by Licensor or any Affiliate thereof, or subject to an obligation of assignment to Licensor or any Affiliate thereof, Covering or relating to any portion of the Technology; (c) any additions, divisionals, continuations, continuations-in-part, conversion, supplemental examinations, extensions, term restorations, registrations, re-instatements, amendments, reissuances, corrections, substitutions, re-examinations, registrations, revalidations, supplementary protection certificates, renewals, and foreign counterparts of the Initial Licensor Patents or the Patents described in (b) above, and any other Patents owned, controlled, or licensed by Licensor claiming priority to any of the foregoing or any of the Patents referenced in clause (a) or (b) above; and (d) all patents issuing from any of the Patents mentioned in clause (a), (b), or (c) above and any foreign counterparts of any such Patents, and which shall include, in any case, patents surviving post grant review and inter partes review.
US patent 6,585,995 Methods and compositions for treating platelet-related disorders
US Patent Application 20130022671
Product means a product that is Covered by one or more Licensor Patents in any country in which such product or any part thereof is made, used, or sold.
Licensor Technology means the Licensor Know-How and the Licensor Patents.
Patent(s) means any granted or issued patents and pending patent applications, together with all additions, divisionals, continuations, continuations-in-part, substitutions, reissues, re-examinations, supplemental examinations, patents reviewed under post grant review or inter partes review, extensions, registrations, patent term extensions, revalidations, supplementary protection certificates, and renewals of any of the foregoing, and all foreign applications and patents corresponding to or claiming priority from any of the foregoing.
Essential thrombocythemia (ET) is a rare chronic blood cancer (myeloproliferative neoplasm) characterised by the overproduction of platelets (thrombocytes) by megakaryocytes in the bone marrow.
Cardiovascular Field means the direct prevention, treatment, diagnosis of myocardial infarction, strokes and peripheral arterial disease in humans or other animals. For sake of clarity the Cardiovascular Field will not include the prevention, treatment or diagnosis of conditions that may ultimately lead to a decrease in the risk of thrombotic events, such as Myeloproliferative Disorders and other hematological indications.
IPSCIO Record ID: 291107
Collaborator Patent Right means any Patent Right that (a) is Controlled by Collaborator or any of its Affiliates as of the Effective Date (including the Collaborator Patent Rights that comes into the Control of Collaborator or any of its Affiliates during the Term (other than through the grant of a license by Licensee) and (b) claims or discloses any (i) Antibody or Product (including the composition of matter thereof), (ii) method of making any Antibody or Product or materials used in any method of making any Antibody or Product, or (iii) methods of using any Antibody or Product.
Collaborator Technology means the Collaborator Patent Rights and Collaborator Know-How.
Patent Rights means any and all (a) issued patents, (b) pending patent applications, including all provisional applications, substitutions, continuations, continuations-in-part, divisions and renewals, and all patents granted thereon, (c) patents-of-addition, reissues, reexaminations and extensions or restorations by existing or future extension or restoration mechanisms, including patent term adjustments, patent term extensions, supplementary protection certificates or the equivalent thereof, (d) inventorâ€™s certificates, (e) other forms of government-issued rights substantially similar to any of the foregoing and (f) United States and foreign counterparts of any of the foregoing.
IPSCIO Record ID: 194532
Title: Sonochemical coating of textiles with Metal Oxide Nanoparticles for Antimicrobial Fabrics
PCT no.: PCT/IL2009/000645
IL â€“ appl. no. 209908, filed 29-06-2009
US â€“ appl. no. 12/997,276, filed on 10-Dec-2010
EU â€“ appl. no. 09773041.0, 06-01-2011
Title: Doped Metal Oxide Nanoparticles of and uses thereof
PCT/IL2014/050406, filed on 05-May-2014
Patent Rights means, in each case to the extent owned and controlled by Licensor: (a) the patent applications listed in Exhibit B; (b) any patent or patent application that claims priority to and is a divisional, continuation, reissue, renewal, reexamination, substitution or extension of any patent application identified in (a); (c) any patents issuing on any patent application identified in (a) or (b), including any reissues, renewals, reexaminations, substitutions or extensions thereof; (d) any claim of a continuation-in-part application or patent (including any reissues, renewals, reexaminations, substitutions or extensions thereof) that is entitled to the priority date of, and is directed specifically to subject matter specifically described in, at least one of the patents or patent applications identified in (a), (b) or (c); (e) any foreign counterpart (including PCTs) of any patent or patent application identified in (a), (b) or (c) or of the claims identified in (d); and (f) any supplementary protection certificates, pediatric exclusivity periods, any other patent term extensions and exclusivity periods and the like of any patents and patent applications identified in (a) through (e).
Licensed Product means any bed linen, drapery, upholstery, home textile and/or clothing that contains Covered Textile.
IPSCIO Record ID: 294019
Licensed Patents means that certain U.S. Patent No. 5,310,562; and all corresponding foreign patent applications and patents throughout the Territory, including any and all divisions, re-issues, re-examinations, renewals, continuations and substitutes in whole or in part of such patents and patent applications in the Territory with respect to the anti-fibrotic uses of Pirfenidone; and all Patents defined. The Licensed Patents shall specifically exclude U.S. Patent No. 5,962,478 titled Tumor Necrosis Factor Alpha.
5,310,562 – Composition and method for reparation and prevention of fibrotic lesions
Patents means all of Licensors (a) anti-fibrotic, Pirfenidone patent applications heretofore or hereafter filed or having legal force in any country including without limitation divisionals, continuations, continuation-in-part and provisional applications; (b) issued, unexpired anti-fibrotic Pirfenidone patents in any country, including utility, model and design patents and certificates of invention; and (c) substitutions, extensions, reissues, renewals, and supplementary protection certificates with respect to any such issued patents. For clarity, such patent applications and patents shall include those owned, as well as those controlled with the right to grant licenses, by any of Licensors. The Patents shall not include patent applications and patents to the extent claiming uses of Pirfenidone other than for anti-fibrotic uses, nor uses of compounds for anti-fibrotic applications other than Pirfenidone.
Fibrosis, also known as Fibrotic scarring, is a pathological wound healing in which connective tissue replaces normal parenchymal tissue to the extent that goes unchecked, leading to considerable tissue remodelling and the formation of permanent scar tissue.
IPSCIO Record ID: 248293
Within 15 days of the Commencement Date, Licensor shall transfer and deliver to Licensee in good order the Documentation.
With effect from the Commencement Date, all right, title and interest in the Documentation and the Ancillary Rights shall vest in Licensee. Licensor shall at the request of Licensee promptly do all acts and execute all documents as may be necessary or desirable to vest in Licensee all right, title and interest in the Documentation and the Ancillary Rights.
In the event the development, making, having made, use, or sale of Products by Licensee, its Affiliates or Licensees would infringe any other intellectual property which Licensor owns at the Commencement Date or has the rights to license (other than the Patents, Know How, Documentation and Ancillary Rights), Licensor hereby grants to Licensee, a non-exclusive, world-wide, royalty-free, sub-licensable license under such other intellectual property solely for Licensee, and its Affiliates and Licensees to develop, make, have made, use and sell Products.
US Patent: 6,583,265 – Cyclosporins
Ciclosporin, also spelled cyclosporine and cyclosporin, is an immunosuppressant medication and natural product.
Products means any product containing a Compound.
Compound means a Compound ELL-1 or a Compound LUCH-1.
Compound ELL-1 any compound, whose manufacture, sale or use falls within the scope of a Valid Claim of ELL-1. Included are any and all compounds whose manufacture passes the Intermediate as defined in Claim 1, formula VI of US 6,583,265 (hereinafter called Cation);
Compound LUCH-1 any compound, whose manufacture, sale or use falls within the scope of a Valid Claim of LUCH-1. Included are any and all compounds, whose manufacture passes the Intermediate Polyanion of 4-(gamma-hydroxy)-N-methylleueineuyclosporin (hereafter called Polyanion), namely the compound 3-alpha-(2-N,N-dimethylamino)-ethylthio-4-(gamma-hydroxy-Me-Lue)-cyclosporin or a salf thereof.
IPSCIO Record ID: 245900
U.S. provisional patent application USSN 60/965,135 entitled Therapeutic Compositions for Treatment of Inflammation of Ocular and Adnexal Tissues
PCT/US08/09776 filed on 15.08.2008 claiming priority to Provisional 60/965,135, filed on August 16 2007. Published on February 26, 2009 WO/2009/025763, entitled Therapeutic Compositions for Treatment of Inflammation of Ocular and Adnexal Tissues
Provisional 61/143,561 filed January 09. 2009 entitled Therapeutic Compositions For Treatment of Corneal Disorders
Licensed Product means any product the manufacture, use or sale of which would, but for the licenses granted in this Agreement, infringe a Valid Claim of a Licensed Patent.
An amendment to the license agreement dated 01/01/1990 is amended by deleting it in its entirety the above Licensed Patent Information and replacing it hereto:
U.S. Patent Appln. No. 121685.510
U.S. Patent Appln. No. 13/183,231
IPSCIO Record ID: 291171
Licensor Intellectual Property means the Licensor Know-How, the Licensor Patents, the Licensor Improvements and the Product Patents.
Licensor Patents means any and all Patent Rights now existing, currently pending or hereafter filed by Licensor relating to the Licensor Technology.
Licensor Technology means the SODASÃ¢ oral controlled release formulation technology that comprises the formation of 0.5-5mm beads containing an active agent and excipients which can be coated with a product-specific modified release polymer and then formulated into a final formulation such as a sprinkle, a tablet or a capsule, as applied in the Licensor Know-How.
Licensor Trademark means SODASÂ® or such other trade marks as Licensor may from time to time reasonably specify.
Licensor Improvements means any and all improvements to the Licensor Patents, the Licensor Know-How, the Licensor Technology and/or the Product Patents that have been conceived, created, developed and/or otherwise invented by Licensor and/or Licensee under the R&D Program, or otherwise pursuant to this Agreement.
Patent Rights means any and all rights under any and all patent applications and/or issued or granted patents, now existing, currently pending or hereafter filed, including, but not limited to, provisional applications, substitutions, divisionals, continuations, continuations-in-part, renewals and any foreign counterparts thereof or equivalents thereto, including the right to claim priority from any of the foregoing under the Paris Convention, and all patents issuing or granted on any of the foregoing, and any foreign counterparts thereof, together with all registrations, reissues, re-examinations, supplemental protection certificates, or extensions thereof, and any foreign counterparts thereof, or any other government-issued rights substantially equivalent to the foregoing.
BiDil means the existing immediate release product containing the Compound that is currently marketed in the United States by Licensee.
Compound means the combination of the active drug substances isosorbide dinitrate and hydralazine HCl and/or other salts, bases and isomeric forms of each.
IPSCIO Record ID: 240572
Licensor Patent Rights means all Patents in any country within the Territory which are owned or Controlled by Licensor as of the Effective Date or during the term of this License Agreement that claim the manufacture, use or sale of a Product (including, without limitation, any formulation, process of manufacture, or method of use of such Product).
Joint Patent Rights shall mean those Patents claiming inventions made jointly by one (1) or more employees or consultants of each Party or otherwise listed hereto. Joint Patent Rights as they exist as of the Effective Date are set forth hereto.
10/146,138 – SUBSTITUTED 4H-CHROMENES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF
10/146,136 – Substituted COUMARINS AND QUINOLINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF
Patent (which term may be used either in the singular or plural form) means any patent and patent applications, and all additions, divisions, continuations, continuations in-part, pipeline protection, substitutions, reissues, extensions, registrations, patent term extensions, supplementary protection certificates and renewals of any of the above.
IPSCIO Record ID: 273247
Licensed Patent Rights shall mean the Patent Rights, the Non-exclusive Patent Rights and Research Patent Rights.
Research Patent Rights shall mean any United States and/or non-United States patent or patent applications and all substitutions, divisions, continuations, continuations-in-part, reissues, reexaminations and extensions thereof that are owned or otherwise controlled by the Licensor and that cover the Know-how and/or Research Know-how developed prior to or during the course of the Research Program.
Patent Rights shall mean: The patent application set forth, designated as exclusive; Any non-United States patent applications claiming priority from the patent application referred to; Claims of United States continuation-in-part applications, and of the resulting patents; and Any reissues, divisionals, amendments or extensions of the United States or non-United States patents.
Exclusive Patent Rights: New Heterocyclic compounds, method of developing new drug leads and combinatorial libraries used in such method.
Non-exclusive Patent Rights: A general procedure for the preperative scale systhesis of protected Ca (functionalysed alkyl) amino acids suitable for solid phase synthesis.
Exclusive Know-How: All new developments, now in existence or to be developed pursuant to the Research Program.
Non-Exclusive Know-How: The novel building units described in Agreement and a process for the preparation of compounds described in the Agreement consisting of a multistep reaction procedure.
Non-Exclusive Patent Rights shall mean the provisional patent application set forth in this Agreement designated as non-exclusive; Any United States utility patent application and non-United States patent applications based, in whole or in part, on the provisional patent application set forth; The United States and non-United States patents issued from the applications referred to; Claims of United States continuation-in-part applications, and of the resulting patents, which are based on the subject matter specifically described; and Any reissues, divisionals, amendments or extensions of the United States or non-United States patents described.